China Pharma Holdings logo

China Pharma HoldingsNYSE American: CPHI

Profile

Sector:

Healthcare

Country:

China

IPO:

17 April 2002

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$3.99 M
-87%vs. 3y high
11%vs. sector
-vs. 3y high
-vs. sector
-86%vs. 3y high
30%vs. sector
-77%vs. 3y high
19%vs. sector

Price

after hours | 57 min ago
$0.21-$0.00(-0.96%)

Dividend

No data over the past 3 years
$1.10 M-$1.12 M

Analysts recommendations

Institutional Ownership

CPHI Latest News

West Wins Heart of Pharma Award at 2024 CPHI Pharma Awards
prnewswire.com09 October 2024 Sentiment: POSITIVE

EXTON, Pa. , Oct. 9, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, is pleased to announce that it has been awarded the Heart of Pharma Award at the 2024 CPHI Awards for its partnership with Fox Chase Cancer Center, a part of the Temple University Health System. This award recognizes companies, individuals, and initiatives which nurture philanthropic, ethical and community-based ventures.

West to Attend and Showcase Industry Leadership in Packaging and Containment at CPHI Worldwide Conference
prnewswire.com07 October 2024 Sentiment: POSITIVE

EXTON, Pa. , Oct. 7, 2024  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced its participation at CPHI Worldwide in Milan, Italy to showcase leadership and expertise on industry challenges and trends in packaging and containment. This year, West will highlight its industry expertise through a technical-focused presentation: Examining Contamination Control Strategy in Primary Packaging as part of EU GMP Annex 1- Wednesday, October 9 | 2:15 - 2:40 p.m.

Thermo Fisher Scientific Showcases Expanded Biopharma Services, Capabilities and Innovations at CPHI Milan 2024
businesswire.com07 October 2024 Sentiment: POSITIVE

MILAN--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, will showcase its latest innovations enabling the molecule-to-medicine journey and host a series of sessions that feature industry developments during CPHI Milan 2024, Oct. 8-10, in Milan, Italy. Leaders and experts from the company will be present at conference booth #7B18 to discuss how Thermo Fisher is supporting biotechnology and pharmaceutical companies across indications, modalities, sizes and stag.

China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025
prnewswire.com19 August 2024 Sentiment: POSITIVE

HAIKOU, China , Aug. 19, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that through Hainan Helpson Medical and Biotechnology Co., Ltd. ("Helpson"), our wholly owned subsidiary, it expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 in China.

What type of business is China Pharma Holdings?

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

What sector is China Pharma Holdings in?

China Pharma Holdings is in the Healthcare sector

What industry is China Pharma Holdings in?

China Pharma Holdings is in the Drug Manufacturers - Specialty & Generic industry

What country is China Pharma Holdings from?

China Pharma Holdings is headquartered in China

When did China Pharma Holdings go public?

China Pharma Holdings initial public offering (IPO) was on 17 April 2002

What is China Pharma Holdings website?

https://www.chinapharmaholdings.com

Is China Pharma Holdings in the S&P 500?

No, China Pharma Holdings is not included in the S&P 500 index

Is China Pharma Holdings in the NASDAQ 100?

No, China Pharma Holdings is not included in the NASDAQ 100 index

Is China Pharma Holdings in the Dow Jones?

No, China Pharma Holdings is not included in the Dow Jones index

When was China Pharma Holdings the previous earnings report?

No data

When does China Pharma Holdings earnings report?

Next earnings report date is not announced yet